NEW YORK, NY--(Marketwire - June 25, 2010) - Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview® (EIO®) on TapImmune Inc. (
TapImmune Inc. ("TapImmune" or "the Company") develops innovative immunotherapeutics to treat cancer and prevent infectious disease. Its product candidates are based on a core technology platform of transporters associated with antigen processing (TAP) -- proteins that have a crucial role in the presentation of cancer markers on the surface of tumor cells. When TAP proteins are poorly expressed, tumors may go undetected by the immune system, progressing and possibly metastasizing (spreading) to other areas of the body.
One of the Company's lead initiatives -- a therapeutic cancer vaccine called AdhTAP1 -- aims to increase TAP expression in tumor cells in order to restore the immune system's ability to recognize and attack cancerous cells. Proof of principle for AdhTAP1 has been established through over 10 years of research at the University of British Columbia. TapImmune is preparing to initiate clinical manufacturing and toxicology studies for AdhTAP1 and submit an Investigational New Drug (IND) application in the U.S. and abroad in late 2011.
As well, the Company is sponsoring the clinical development of a vaccine technology for breast cancer patients who express the HER-2/neu receptor, an indication of a more aggressive form of cancer. Phase I trials are expected in early 2011 at the Mayo Clinic in Rochester, Minnesota. TapImmune also aims to develop safe and effective preventive vaccines for infectious diseases (e.g., smallpox, influenza, and tuberculosis) based on findings that increasing TAP expression may augment the immune system's response to an infection.
TapImmune plans to manage the development of its vaccine candidates through the Phase I/II proof-of-concept stage. In addition to its use as a stand-alone vaccine, TapImmune may be able to position the TAP technology as a "vaccine component" that improves the efficacy and potency of other vaccines.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small- and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview® (EIO®), is free of investment ratings, target prices, and forward-looking financial models. The EIO® presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO® details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, West Palm Beach, Montréal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of forty-two thousand five hundred dollars and two hundred thousand options/warrants to purchase TapImmune's stock for its services in creating this report, for updates, and for printing costs.
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with the SEC.
These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.
Contact Information:
Contact:
Jeffrey J. Kraws/Karen B. Goldfarb
Crystal Research Associates, LLC
P: (609) 306-2274
F: (609) 395-9339